PET/MRT in der diagnostik gastrointestinaler tumoren

F. C. Gaertner; M. Eiber; A. J. Beer; S. Fürst; S. I. Ziegler; M. Schwaiger; A. Drzezga

doi:10.1007/s11377-012-0671-0

PET/MRT in der diagnostik gastrointestinaler tumoren

Translated title of the contribution: PET/MRI in diagnosis of gastrointestinal tumors

F. C. Gaertner
, M. Eiber
, A. J. Beer
, S. Fürst
, S. I. Ziegler
, M. Schwaiger
, A. Drzezga

Technical University of Munich

Research output: Contribution to journal › Article › peer-review

Abstract

The first fully integrated combined positron emission tomography/magnetic resonance imaging (PET/MRI) scanners have been undergoing clinical testing since 2010. Due to the increased soft tissue contrast of MRI advantages of this technology are anticipated in body regions where MRI is known to be superior to computed tomography (CT), such as in the upper abdomen (liver, pancreas) and the pelvis. Improvements are to be expected in the diagnosis of hepatic metastases, regarding M-staging and relapse of colorectal cancer and neuroendocrine tumors. However, the definitive clinical value of PET/MRI now remains to be evaluated in clinical trials.

Translated title of the contribution	PET/MRI in diagnosis of gastrointestinal tumors
Original language	German
Pages (from-to)	249-254
Number of pages	6
Journal	Gastroenterologe
Volume	7
Issue number	3
DOIs	https://doi.org/10.1007/s11377-012-0671-0
State	Published - May 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s11377-012-0671-0

Cite this

@article{99777f9b9679433d8d1b4dba58817bf2,

title = "PET/MRT in der diagnostik gastrointestinaler tumoren",

abstract = "The first fully integrated combined positron emission tomography/magnetic resonance imaging (PET/MRI) scanners have been undergoing clinical testing since 2010. Due to the increased soft tissue contrast of MRI advantages of this technology are anticipated in body regions where MRI is known to be superior to computed tomography (CT), such as in the upper abdomen (liver, pancreas) and the pelvis. Improvements are to be expected in the diagnosis of hepatic metastases, regarding M-staging and relapse of colorectal cancer and neuroendocrine tumors. However, the definitive clinical value of PET/MRI now remains to be evaluated in clinical trials.",

keywords = "Gastrointestinal tumors, Liver metastasis, Neuroendocrine tumors, Positron-emission tomography and computed tomography (PET/CT), Positron-emission tomography and magnetic resonance imaging (PET/MRI)",

author = "Gaertner, \{F. C.\} and M. Eiber and Beer, \{A. J.\} and S. F{\"u}rst and Ziegler, \{S. I.\} and M. Schwaiger and A. Drzezga",

year = "2012",

month = may,

doi = "10.1007/s11377-012-0671-0",

language = "Deutsch",

volume = "7",

pages = "249--254",

journal = "Gastroenterologe",

issn = "1861-9681",

publisher = "Springer Medizin",

number = "3",

}

TY - JOUR

T1 - PET/MRT in der diagnostik gastrointestinaler tumoren

AU - Gaertner, F. C.

AU - Eiber, M.

AU - Beer, A. J.

AU - Fürst, S.

AU - Ziegler, S. I.

AU - Schwaiger, M.

AU - Drzezga, A.

PY - 2012/5

Y1 - 2012/5

N2 - The first fully integrated combined positron emission tomography/magnetic resonance imaging (PET/MRI) scanners have been undergoing clinical testing since 2010. Due to the increased soft tissue contrast of MRI advantages of this technology are anticipated in body regions where MRI is known to be superior to computed tomography (CT), such as in the upper abdomen (liver, pancreas) and the pelvis. Improvements are to be expected in the diagnosis of hepatic metastases, regarding M-staging and relapse of colorectal cancer and neuroendocrine tumors. However, the definitive clinical value of PET/MRI now remains to be evaluated in clinical trials.

AB - The first fully integrated combined positron emission tomography/magnetic resonance imaging (PET/MRI) scanners have been undergoing clinical testing since 2010. Due to the increased soft tissue contrast of MRI advantages of this technology are anticipated in body regions where MRI is known to be superior to computed tomography (CT), such as in the upper abdomen (liver, pancreas) and the pelvis. Improvements are to be expected in the diagnosis of hepatic metastases, regarding M-staging and relapse of colorectal cancer and neuroendocrine tumors. However, the definitive clinical value of PET/MRI now remains to be evaluated in clinical trials.

KW - Gastrointestinal tumors

KW - Liver metastasis

KW - Neuroendocrine tumors

KW - Positron-emission tomography and computed tomography (PET/CT)

KW - Positron-emission tomography and magnetic resonance imaging (PET/MRI)

UR - https://www.scopus.com/pages/publications/84860888302

U2 - 10.1007/s11377-012-0671-0

DO - 10.1007/s11377-012-0671-0

M3 - Artikel

AN - SCOPUS:84860888302

SN - 1861-9681

VL - 7

SP - 249

EP - 254

JO - Gastroenterologe

JF - Gastroenterologe

IS - 3

ER -

PET/MRT in der diagnostik gastrointestinaler tumoren

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this